- Anat Loewenstein is Professor of Ophthalmology and Director of the Department of Ophthalmology, Tel Aviv Medical Center, Incumbent of the Sydney A. Fox Chair in Ophthalmology and Vice Dean at the Sackler Faculty of Medicine, Tel Aviv University, Israel. In addition, she is the Head of the Ethical Committee of the Israel Ministry of Health. Her research and clinical interests focus on age-related macular degeneration, especially early detection and treatment modalities, retinal vein occlusion, diabetic retinopathy and drugs toxicity to the retina. Professor Loewenstein is a board member in the Euretina, the international representative at the ASRS, as well as member in SOE, AAO, ARVO, Macula Society, Retina Society, Club Jules Gonin. With more than 200 presentations and 280 publications in to medical journals and books, she frequently lectures as an invited professor to international meetings. She is the editor of the journal "Case reports in Ophthalmology" and on the editorial board of the journals Retina, Graefes Archives of Clinical and Experimental Ophthalmology, OSNE and European Journal of Ophthalmology.Anat Loewenstein, MD, MHAProfessor of Ophthalmology, Tel Aviv Medical Center, Israel
- n/aAkihiro Ohira, MD, Ph.D.Professor at the Department of Ophthalmology, Shimane University School of Medicine, Japan
- Dr. Nicholas Bodor is a Graduate Research Professor Emeritus (active) at the University of Florida College of Pharmacy, Gainesville. He joined the university in 1979 as Professor and Chairman of the Medicinal Chemistry Department, and was promoted to Graduate Research Professor in 1983. He is the Executive Director of the college’s Center for Drug Discovery, founded by him in 1986. During his tenure at the University of Florida, Dr. Bodor has supervised the training of more than 50 doctoral students and over 100 postdoctoral level research associates and fellows.Nicholas Bodor, Ph.D.Graduate Research Professor Emeritus (active) at the University of Florida College of Pharmacy, Gainesville
He has published more than 520 research articles, has over 240 patents, and is on the editorial boards of several international scientific journals. In February 2000, he took a leave of absence from his academic posts at the University of Florida in order to accept a position as Senior Vice President of Basic Research and Drug Discovery at the IVAX Corporation. Dr. Bodor then served as Chief Scientific Officer of the IVAX Corporation, Managing Director of the IVAX Drug Research Institute, Budapest, Hungary, as well as President of the IVAX Research Institute until October 2005. He founded Bodor Laboratories, Inc. in 2006, to further develop his drug design strategies to the marketplace.
- n/aMaria Soffia Gottfredsdottir, MDOphthalmologist, the National University Hospital of Iceland
- n/aJost B. Jonas, MD, Ph.D.Professor of Ophthalmology, Chairman of the Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg , Germany
- Dr. George Mooney has over 30 years industrial experience, most recently as VP for the Exploratory Development Portfolio at Pfizer, as well as VP of Pharmaceutical Sciences, Pfizer Europe. While extensively experienced in the CMC area (Chemistry, Manufacturing and Controls’) he has lead and managed multi-disciplinary Teams at all stages of Drug Development. Other former companies include at GD Searle, Boehringer Ingelheim (USA) and American Cyanamid (Lederle) Co. Dr Mooney has been associated with 30+ NDAs and sNDA’s, most notably Voriconazole (Vfend®oral and IV for the acute treatment of Aspergillosis which required co-development of special excipient) and Viagra®(Sildenifil for the treatment of Erectile Dysfunction). Additionally, throughout his career he has been responsible for over 80 IND filings, primarily covering NCE’s across the majority of therapeutic areas and associated routes of delivery (Oral, Parenteral, Inhalation, Topical and Ophthalmic). Significant Topical and Ophthalmic experience has been gained in the development of Prostaglandins, Antibiotics and most recently a novel peptide for the treatment of AMD. He qualified as a Pharmacist in the UK (B.Pharm, MSc University of London) and gained his PhD at University of Kansas in Pharmaceutical Sciences. He is a William Pitt Fellow at Pembroke College Cambridge UK, a member of the American Association of Pharmaceutical Scientists and of the Royal Pharmaceutical Society of Great Britain and is currently a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture (MMV). He is also the author of a number of Patents in the field of Drug Delivery.K. George Mooney, Ph.D..